Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1R ) and receptor-5 (S1P5R ) agonist with autoimmune disease-modifying activity.
Treatment of relapsing-remitting multiple sclerosis with high-dose cyclophosphamide induction followed by glatiramer acetate maintenance.
Tumefactive multiple sclerosis lesions under fingolimod treatment.
Genzyme’s Lemtrada™ approved in Canada for treatment of multiple sclerosis
Laminin-411 Is a Vascular Ligand for MCAM and Facilitates TH17 Cell Entry into the CNS.
Potential of a unique antibody gene signature to predict conversion to clinically definite multiple sclerosis.
[Budget impact analysis of the first-line treatment of relapsing remitting multiple sclerosis in Spain. Reply].
Periventricular lesions help differentiate neuromyelitis optica spectrum disorders from multiple sclerosis.
ATX-MS-1467, An Immunotolerizing Agent, Halts Disease Progression and Reduces CNS Inflammation in Rodent Models of Multiple Sclerosis (P1.216)
Optimizing parameter choice for FSL-Brain Extraction Tool (BET) on 3D T1-images in multiple sclerosis.
Amiloride Clinical Trial In Optic Neuritis (ACTION) protocol: a randomised, double blind, placebo controlled trial.
Editorial for JNV issue on PML.
Acorda Therapeutics announces positive AMPYRA® (dalfampridine) Phase 2 data in people with post-stroke deficits
Benefit of additional screening for progressive multifocal leukoencephalopathy in patients with multiple sclerosis taking natalizumab: a decision analysis.
Assessment of the effect of interferon-beta1a therapy on thyroid and salivary gland functions in patients with multiple sclerosis using quantitative salivary gland scintigraphyz.
Modulation of dendritic cell properties by laquinimod as a mechanism for modulating multiple sclerosis.
Glatiramer acetate-induced hepatitis in a young female patient with multiple sclerosis.
Molecular targets of FTY720 (fingolimod).
The OSCAR-IB Consensus Criteria for Retinal OCT Quality Assessment.
Enhancement of endocannabinoid signaling by fatty acid amide hydrolase inhibition: a neuroprotective therapeutic modality.
Review of subcutaneous interferon β-1a, delivered via the electronic self-injection device RebiSmart™, for the treatment of multiple sclerosis.
Amiloride HCl
Teva Announces Approval of Three-Times-A-Week COPAXONE® 40 mg/mL in Russia for the Treatment of Relapsing-Remitting Multiple Sclerosis
Exploring the CLEC16A gene reveals a MS-associated variant with correlation to the relative expression of CLEC16A isoforms in thymus.
Blockade of the High-Affinity Interleukin-2 Receptors with Daclizumab High-Yield Process: Pharmacokinetic/Pharmacodynamic Analysis of Single- and Multiple-Dose Phase I Trials.

Pages